V8 Peptides — Engineered Performance
Research Library
CJC-1295 Mechanism of Action: GHRH Receptor Signaling
CJC-1295 No DACMechanism

CJC-1295 Mechanism of Action: GHRH Receptor Signaling

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How does CJC-1295 work? It is a GHRH analog: it binds the GHRH receptor, a Gs-coupled class B receptor on pituitary somatotrophs, raising intracellular cAMP and activating protein kinase A, which promotes GH gene expression and the release of stored GH. Hypothalamic somatostatin acts as the opposing brake, and the pattern of GH output reflects both. The no-DAC form adds no new mechanism to native GHRH; its substitutions change how long the ligand survives. Sold by V8 for laboratory research use only.

“Mechanism of action” is often reduced to one sentence. For bench work it is better regarded as a chain of measurable steps, each with an assay, a time scale and a typical failure mode. This article lays out that chain for CJC-1295 without DAC (modified GRF 1-29), using the primary literature for the receptor and the axis. It leaves out the history, which is in the CJC-1295 No DAC overview, and the form comparison, which is in DAC versus no DAC. For laboratory research use only; not for human consumption.

The ligand: a stabilized fragment of the native hormone

The active information of the 44-residue hormone sits in its first 29 residues (Guillemin and colleagues, 1982). The peptide on the CJC-1295 (No DAC) product page is that fragment with protective substitutions (D-Ala at position 2, Gln at 8, Ala at 15) and a C-terminal amide. Position 2 matters for stability because plasma dipeptidyl-aminopeptidase removes the first two residues from native GHRH to make an almost inactive product (Frohman and colleagues, 1986). Mechanistically the analog is an agonist at the same receptor as the hormone; substitutions affect survival and not the choice of receptor.

Step 1: binding the GHRH receptor

Mayo (1992) isolated a cDNA from rat pituitary encoding a G-protein-coupled receptor with seven membrane-spanning domains, expressed the human homolog in human kidney 293 cells, and showed that membranes bound human GHRH with high affinity and specificity. The receptor is homologous to receptors for secretin and vasoactive intestinal peptide, ligands related to GHRH, which places it in the class B family. Its mRNA was expressed predominantly in the pituitary.

Step 2: Gs, adenylate cyclase and cAMP

In the same study, GHRH stimulated intracellular cAMP production in cells expressing the receptor (Mayo, 1992). The canonical route is receptor activation of Gs, stimulation of adenylate cyclase, a rise in cAMP and activation of protein kinase A. This is the readout most laboratories use because it is fast and quantitative.

StepEventCommon assayTime scale
1Ligand binding to the GHRH receptorRadioligand or fluorescent binding in membranesSeconds to minutes
2Gs activation, cAMP productioncAMP immunoassay or biosensorMinutes
3Protein kinase A activity and phosphorylation of targetsPhospho-specific immunoblot; reporter geneMinutes to an hour
4GH release from stored granulesGH immunoassay of mediumMinutes to hours
5GH gene expression and somatotroph growthGH mRNA by qPCR; proliferation markersHours to days

The upper rows are specific to receptor engagement; the lower rows integrate many inputs. A dose or concentration response is most interpretable at steps 1 to 3 and becomes progressively more confounded further down.

Step 3: from cAMP to GH release and synthesis

Downstream of protein kinase A, the pituitary response has two arms: acute release of stored GH and slower upregulation of GH gene transcription. Evidence for the slow arm in an animal model comes from the GHRH knockout mouse, where lack of GHRH reduced pituitary GH mRNA and protein (Alba and Salvatori, 2004), and where administration of CJC-1295 increased total pituitary RNA and GH mRNA, which the authors read together with immunohistochemistry as somatotroph proliferation (Alba and colleagues, 2006). Evidence for the acute arm comes from the GH secretion assay in cultured rat anterior pituitary cells and from plasma GH in rats after administration of the albumin-binding analog (Jetté and colleagues, 2005).

The counterweight: somatostatin and pulsatility

GHRH alone does not set the pattern of GH secretion. Tannenbaum and Ling (1984) described the interrelationship of GHRH and somatostatin in generating the ultradian rhythm of GH secretion in rats. In practice the cell’s response to a given GHRH signal depends on the inhibitory tone present at that moment, and in culture on whether any somatostatin is in the medium. The ghrelin-receptor pathway, the target of secretagogues such as ipamorelin, is a further input to the same cell. Pairing a GHRH analog with a secretagogue is therefore a way to probe two inputs at once, which is why CJC-1295 and ipamorelin are so often studied together.

Input on the somatotrophReceptorEffect on GH outputExample ligand
GHRHGHRH receptor (Gs-coupled)Stimulates release and synthesisCJC-1295, sermorelin
SomatostatinSomatostatin receptorsInhibits releaseNative somatostatin
Ghrelin-type inputGHS-R1aStimulates release through a separate receptorIpamorelin, GHRP-2

Duration of the signal matters. Pulsatile exposure to GRF(1-29)NH2 promoted growth in rats whereas continuous exposure did not (Clark and Robinson, 1985). A short-acting analog allows an experimenter to impose a pulse; a long-acting conjugate does not.

Assay design: matching each step to an experiment

  1. Receptor-level work. Use a cell line expressing the GHRH receptor, a serum-free buffer and short incubation. Include a native GHRH or sermorelin reference and a vehicle. The no-DAC peptide is exposed to peptidases in serum, so keep media simple.
  2. Signaling kinetics. Time-course cAMP with a phosphodiesterase inhibitor if the question is accumulation, and without if the question is net signaling.
  3. Secretion. Primary or dispersed pituitary cells, with GH measured in medium. Add somatostatin to test counter-regulation.
  4. Chronic effects. Animal models, as in the knockout work, with defined schedules and controls.

Concentrations are prepared from the vial mass and the diluent volume (concentration = mass ÷ volume); the calculator shows the arithmetic and the reconstitution method covers dissolving the powder.

What the mechanism does not say

A mechanism is a pathway, not a claim of any effect outside the models studied. The pathway above is established for GHRH and for the albumin-binding analog in rodents; for the no-DAC peptide it is inferred from its structure as a modified GHRH(1-29), and primary data specific to it are limited. Selectivity for the GHRH receptor versus related class B receptors is a property that should be tested in a given assay, given the homology Mayo (1992) noted with secretin and VIP receptors. The comparison with a relative that uses a different stabilization strategy is in tesamorelin versus CJC-1295. Quality documentation, where published, is in the COA library, and the sequence conventions are in understanding amino acid sequences.

Frequently asked questions

What receptor does CJC-1295 act on?

The GHRH receptor, a seven-transmembrane G-protein-coupled receptor of the class B family expressed predominantly in the pituitary (Mayo, 1992).

What second messenger is involved?

Cyclic AMP. GHRH stimulates cAMP production in cells expressing the receptor, consistent with Gs coupling.

Does CJC-1295 without DAC have a different mechanism from native GHRH?

No. Its substitutions change stability, not receptor choice. The albumin-binding DAC form changes persistence further.

Why does the D-alanine at position 2 matter?

Plasma dipeptidyl-aminopeptidase removes the first two residues of native GHRH, giving a nearly inactive product. The substitution protects that site.

What opposes GHRH signaling in the axis?

Somatostatin. The interplay of GHRH and somatostatin generates the ultradian rhythm of GH secretion in rats (Tannenbaum and Ling, 1984).

Which assays report receptor activation?

cAMP assays and receptor-binding assays are the most direct. GH release and GH mRNA report slower, more integrated steps.

Why do short and long exposure give different results?

Because the axis is pulsatile. In rats, pulsatile GRF(1-29)NH2 promoted growth while continuous infusion at the same daily amount did not.

Can the mechanism be tested in cell lines?

Yes, in cells expressing the receptor, with a native GHRH reference and a vehicle control. Serum-free conditions simplify interpretation.

How does ipamorelin relate?

Ipamorelin acts on the ghrelin receptor, a separate input to the same somatotroph. The two are studied together to probe both pathways.

Is there data specific to the no-DAC peptide?

Primary data are limited. Its mechanism is inferred from its identity as a modified GHRH(1-29) and from related analogs.

Related reading: CJC-1295 in Metabolic and Endocrine Research Models, CJC-1295 Pharmacokinetics: Half-Life Explained, CJC-1295 Purity: What an HPLC Percentage Cannot Show.

References

  1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
  2. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the N terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
  3. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
  4. Alba M, Salvatori R. A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated GH deficiency. Endocrinology. 2004;145(9):4134-4143. doi:10.1210/en.2004-0119
  5. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
  6. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  7. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-1957. doi:10.1210/endo-115-5-1952
  8. Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008):281-283. doi:10.1038/314281a0

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.